Evidence map›Paper›PMID 28213876›Full record

ReviewCurrent oncology reports2017

Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.

Samantha J Cox, Sean M O'Cathail, Bernadette Coles, Tom Crosby, Somnath Mukherjee

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Samantha J CoxCardiff University, Cardiff, CF10 3XQ, UK. curries@doctors.org.uk.
Sean M O'CathailDepartment of Clinical Oncology, Oxford University NHS Trust, Oxford, UK.
Bernadette ColesLibrary Services, Velindre NHS Trust, Cardiff, UK.
Tom CrosbyDepartment of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
Somnath MukherjeeMRC/CRUK Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Cardiff University · GBOxford University Hospitals NHS Trust · GBUniversity of Oxford · GBVelindre Cancer Centre · GBVelindre NHS Trust · GB

Funding

Cancer Research UK 14614Cancer Research UK 7256
6 · The paper itself

Abstract

Survival outcomes following multimodal treatment of operable oesophageal and gastrooesophageal cancer remain disappointingly poor. Although an appreciation of the impact of both tumour location and histological subtype is now shaping the design of clinical trials, there has been a lack of consensus of the optimal neoadjuvant treatment strategy. This update article will review recent advances in the use of both neoadjuvant chemotherapy and chemoradiotherapy. The emerging role of PET imaging to direct appropriate neoadjuvant treatment regimens and the additive benefit of biological agents are also discussed.

Indexed as

ChemoradiotherapyNeoadjuvant TherapyAdenocarcinomaCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionHumansAdenocarcinomaChemoradiotherapyChemotherapyGastrooesophageal junctionNeoadjuvantOesophagusSquamous cell carcinoma

Identifiers

PMID28213876
PMCPMC5315732
OpenAlexW2588023685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.